Health Care Professionals

Genzyme is committed to providing a high level of support to healthcare professionals. Renvela^® (sevelamer carbonate) provides professionals with an important new treatment option for management of phosphorus without the concerns of calcium or metal accumulation. Renvela offers all the advantages of Renagel^® (sevelamer hydrochloride) with the added benefit of a carbonate buffer. Sevelamer has been studied extensively with more than 150 publications and has been used for 9 years in more than 750,000 patients¹. Renvela is manufactured by Genzyme, a leader in providing treatments for renal patients with mineral and bone disorders.

1. Data on file, Genzyme Corp.

Important Treatment Considerations

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on dialysis. Sevelamer is contraindicated in patients with hypophosphatemia or bowel obstruction. Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery. Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation. Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction. Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer. Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets. For more information, please see Full Prescribing Information for Renvela, Full Prescribing Information for Renagel or call Genzyme Medical Information at 1-800-847-0069.